PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31938055-5	2020	Results: We found that specific impairment of PDGFRbeta kinase activity by 1-NaPP1 treatment efficiently suppressed growth in tumors with high expression of PDGF-BB, i.e. LLC and B16/PDGF-BB, while the clinically used PDGFRbeta kinase inhibitor imatinib did not suppress tumor growth.	imatinib	245-253	platelet derived growth factor receptor, beta polypeptide	Mus musculus	46-55	
31938055-7	2020	Inhibition of PDGFRbeta by either drug impaired tumor vascularization and also affected pericyte coverage; however, specific targeting of PDGFRbeta by 1-NaPP1 resulted in a more pronounced decrease in vessel function with increased vessel apoptosis in high PDGF-BB expressing tumors, compared to treatment with imatinib.	imatinib	311-319	platelet derived growth factor receptor, beta polypeptide	Mus musculus	138-147